178 related articles for article (PubMed ID: 33494672)
1. Recent Advances in the Discovery of GSK-3 Inhibitors from Synthetic Origin in the Treatment of Neurological Disorders.
Saha S; Pal D; Nimse SB
Curr Drug Targets; 2021; 22(12):1437-1462. PubMed ID: 33494672
[TBL] [Abstract][Full Text] [Related]
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
3. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
[TBL] [Abstract][Full Text] [Related]
4. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
[TBL] [Abstract][Full Text] [Related]
5. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?
Leclerc S; Garnier M; Hoessel R; Marko D; Bibb JA; Snyder GL; Greengard P; Biernat J; Wu YZ; Mandelkow EM; Eisenbrand G; Meijer L
J Biol Chem; 2001 Jan; 276(1):251-60. PubMed ID: 11013232
[TBL] [Abstract][Full Text] [Related]
6. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
7. Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease.
Kozikowski AP; Gaisina IN; Petukhov PA; Sridhar J; King LT; Blond SY; Duka T; Rusnak M; Sidhu A
ChemMedChem; 2006 Feb; 1(2):256-66. PubMed ID: 16892358
[TBL] [Abstract][Full Text] [Related]
8. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
9. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo.
Serenó L; Coma M; Rodríguez M; Sánchez-Ferrer P; Sánchez MB; Gich I; Agulló JM; Pérez M; Avila J; Guardia-Laguarta C; Clarimón J; Lleó A; Gómez-Isla T
Neurobiol Dis; 2009 Sep; 35(3):359-67. PubMed ID: 19523516
[TBL] [Abstract][Full Text] [Related]
10. GSK-3 Inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment.
Pal D; Mukherjee S; Song IH; Nimse SB
Curr Drug Targets; 2021; 22(15):1725-1737. PubMed ID: 33459229
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3.
Koh SH; Noh MY; Kim SH
Brain Res; 2008 Jan; 1188():254-62. PubMed ID: 18031715
[TBL] [Abstract][Full Text] [Related]
12. Probing novel 1-aza-9-oxafluorenes as selective GSK-3beta inhibitors.
Voigt B; Krug M; Schächtele C; Totzke F; Hilgeroth A
ChemMedChem; 2008 Jan; 3(1):120-6. PubMed ID: 18000938
[TBL] [Abstract][Full Text] [Related]
13. Perinatal exposure to lead (Pb) promotes Tau phosphorylation in the rat brain in a GSK-3β and CDK5 dependent manner: Relevance to neurological disorders.
Gąssowska M; Baranowska-Bosiacka I; Moczydłowska J; Tarnowski M; Pilutin A; Gutowska I; Strużyńska L; Chlubek D; Adamczyk A
Toxicology; 2016 Mar; 347-349():17-28. PubMed ID: 27012722
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of integrin-linked kinase induces aberrant tau phosphorylation via sustained activation of glycogen synthase kinase 3beta in N1E-115 neuroblastoma cells.
Ishii T; Furuoka H; Muroi Y; Nishimura M
J Biol Chem; 2003 Jul; 278(29):26970-5. PubMed ID: 12714590
[TBL] [Abstract][Full Text] [Related]
15. Parkinson's disease-associated DJ-1 mutations increase abnormal phosphorylation of tau protein through Akt/GSK-3β pathways.
Wang Y; Liu W; He X; Zhou F
J Mol Neurosci; 2013 Nov; 51(3):911-8. PubMed ID: 23979838
[TBL] [Abstract][Full Text] [Related]
16. 17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.
Shi HR; Zhu LQ; Wang SH; Liu XA; Tian Q; Zhang Q; Wang Q; Wang JZ
J Neural Transm (Vienna); 2008 Jun; 115(6):879-88. PubMed ID: 18217188
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells.
Lovestone S; Reynolds CH; Latimer D; Davis DR; Anderton BH; Gallo JM; Hanger D; Mulot S; Marquardt B; Stabel S
Curr Biol; 1994 Dec; 4(12):1077-86. PubMed ID: 7704571
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.
Farr SA; Ripley JL; Sultana R; Zhang Z; Niehoff ML; Platt TL; Murphy MP; Morley JE; Kumar V; Butterfield DA
Free Radic Biol Med; 2014 Feb; 67():387-95. PubMed ID: 24355211
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.
Ferrer I; Barrachina M; Puig B
Acta Neuropathol; 2002 Dec; 104(6):583-91. PubMed ID: 12410379
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.
Selenica ML; Jensen HS; Larsen AK; Pedersen ML; Helboe L; Leist M; Lotharius J
Br J Pharmacol; 2007 Nov; 152(6):959-79. PubMed ID: 17906685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]